ASH 2019 | Zanubrutinib updates from ASH 2019
Constantine Tam
• 10 Dec 2019
Constantine Tam, MBBS (Hons), MD, FRACP, FRCPA, The Peter MacCallum Cancer Centre, Melbourne, Australia, presents two updates on the BTK inhibitor zanubrutinib for chronic lymphocytic leukemia (CLL) and small lymphocytic leukemia (SLL). This includes an update on a phase I/II study which showed high ORR and durable responses irrespective of 17p deletion (NCT02343120), and an update on Arm C of the SEQUOIA trial (NCT03336333), the largest prospective cohort of treatment-naive patients with 17p deletion. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
